Fate and function of exogenously administered mesenchymal stromal cells: current insights and future directions

Overview of attention for article published in Cytotherapy, November 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#21 of 2,003)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 7 news outlets
twitter: 1 X user

bluesky: 2 Bluesky users

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 8 news stories from 7 outlets.

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

BioSpace, 05 Dec 2025

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage…

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as Inmune Bio's CORDStrom?? Platform

MarketScreener, 05 Dec 2025

INmune Bio, Inc. announced a recently published overview of future applications and research areas for mesenchymal stromal cell …

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom(TM) Platform

Stockwatch, 05 Dec 2025

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage…

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

The Manila Times, 05 Dec 2025

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) ("INmune” or the "Company”), a clinical-stage…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 4 additional news stories.